



Published in final edited form as:

Open Inflamm J. ; 4: 49–60. doi:10.2174/1875041901104010049.

Pediatric Sepsis – Part V: Extracellular Heat Shock Proteins: Alarmins for the Host Immune System

John S Giuliano Jr, M.D.¹, Patrick M. Lahni², Hector R. Wong, M.D.^{2,3}, and Derek S. Wheeler, M.D.^{2,3}

¹ Division of Critical Care Medicine, Yale-New Haven Children's Hospital; Department of Pediatrics, Yale University School of Medicine; New Haven, CT

² Division of Critical Care Medicine, Cincinnati Children's Hospital, University of Cincinnati; Cincinnati, OH

³ Department of Pediatrics, University of Cincinnati; Cincinnati, OH

Abstract

Heat shock proteins (HSPs) are molecular chaperones that facilitate the proper folding and assembly of nascent polypeptides and assist in the refolding and stabilization of damaged polypeptides. Through these largely intracellular functions, the HSPs maintain homeostasis and assure cell survival. However, a growing body of literature suggests that HSPs have important effects in the extracellular environment as well. Extracellular HSPs are released from damaged or stressed cells and appear to act as local “danger signals” that activate stress response programs in surrounding cells. Importantly, extracellular HSPs have been shown to activate the host innate and adaptive immune response. With this in mind, extracellular HSPs are commonly included in a growing list of a family of proteins known as danger-associated molecular patterns (DAMPs) or alarmins, which trigger an immune response to tissue injury, such as may occur with trauma, ischemia-reperfusion injury, oxidative stress, etc. Extracellular HSPs, including Hsp72 (HSPA), Hsp27 (HSPB1), Hsp90 (HSPC), Hsp60 (HSPD), and Chaperonin/Hsp10 (HSPE) are especially attractive candidates for DAMPs or alarmins which may be particularly relevant in the pathophysiology of the sepsis syndrome.

Introduction

Virtually all cells respond to stress through the activation of primitive, evolutionarily conserved genetic programs that maintain homeostasis and assure survival. *Stress adaptation* (also known in the literature as *tolerance*, *desensitization*, *conditioning*, or *reprogramming*) is a common paradigm found throughout nature in which a primary exposure of a cell to a stressful stimulus results in an adaptive (frequently protective)

Address for Correspondence: Derek S. Wheeler, M.D. Clinical Director, Division of Critical Care Medicine Medical Director, Pediatric Intensive Care Unit Cincinnati Children's Hospital Medical Center 3333 Burnet Avenue Cincinnati, OH 45229-3039 (513) 636-4259 Tel (513) 636-4267 Fax Derek.wheeler@echmc.org.

Pediatric Sepsis: Markers, Mechanisms, and Management

A Supplement for *Open Inflammation*

Supplement Editor: Derek S. Wheeler, M.D.

response, such that a second exposure to the same stimulus produces a minimal response. More importantly, this adaptive response is not unique to the original stimulus, in that exposure to a different stressful stimulus is also associated with a minimal response. This particular phenomenon is often called *cross-tolerance* or *cross-adaptation* (1-2). The heat shock response is one of the more commonly described forms of stress adaptation and was first described nearly 50 years ago (3-4). The heat shock response, also frequently referred to simply as the *stress response*, is an ancient, highly conserved, endogenous cellular defense mechanism characterized by the rapid upregulation of a specific class of proteins known collectively as heat shock proteins (HSP) or stress proteins (5). The structure, mode of regulation, and function of HSPs are phylogenetically conserved among different species, and HSPs have been isolated from virtually every class of living organism to date, including both prokaryotes and eukaryotes. These proteins range in molecular weight from 7 kDa to 110 kDa and have been found in virtually every part of the cell, including the nucleus, cytoplasm, and mitochondria (1-2, 6-7). By convention, the HSPs are grouped and classified into families based upon their molecular weight, e.g. Hsp70 refers to the 70 kDa family of HSPs, though the nomenclature of human HSPs has recently been standardized (Table 1) (8). Herein, we will refer to both the traditional and standardized nomenclature in order to avoid confusion. There are also an increasing number of proteins that have well defined cellular functions not directly related to cellular stress, but have been demonstrated to be expressed in response to heat shock and other cellular stresses (9-10). These so-called *moonlighting proteins* include ubiquitin (11-12); heme oxygenase (13); inhibitor of κ B, I κ B α (14); endothelial nitric oxide synthase, eNOS (15); and mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) (16).

The HSPs are generally thought to maintain cellular homeostasis by acting as molecular chaperones, facilitating the proper folding and assembly of nascent polypeptides and assisting in the refolding and stabilization of damaged peptides (6-7, 17). Consistent with their function as molecular chaperones, HSPs have traditionally been considered to be exclusively intracellular proteins. However, not long after the HSPs were first discovered, Morton and colleagues (18) discovered a circulating immunosuppressive protein, termed early pregnancy factor (EPF), which was later found to be a mitochondrial HSP known as chaperonin (Cpn)/Hsp10 (HSPE) (19). Later, Hightower and Guidon (20) demonstrated that Hsp70 (HSPA) was released into the extracellular fluid by cultured rat embryo cells in response to thermal stress. Release of Hsp70 (HSPA) occurred in the absence of cell death and was not inhibited by either monensin or colchicine, suggesting that release occurred via a non-classical secretory pathway (see below). More importantly, release was inhibited when these proteins were synthesized in the presence of the lysine analogue aminoethyl cysteine, suggesting that proper folding of Hsp70 (HSPA) was necessary for secretion (20). Since that time, there has been a virtual explosion of literature on the biology of extracellular HSPs. Perhaps even more intriguing is the relatively recent recognition that extracellular HSPs possess the ability to stimulate many cells of the innate and adaptive immune systems (21). Herein, we will briefly review the current roles that extracellular HSPs play in both the innate and adaptive immune responses. We will focus primarily upon host-derived HSPs, rather than bacterial-derived HSPs. Moreover, we will focus primarily upon five specific families of HSPs – Hsp70 (HSPA), Hsp27 (HSPB1), Hsp90 (HSPC),

Hsp60 (HSPD), and Hsp10 (HSPE) as the extracellular roles of these HSP families are the best characterized to date.

Danger Signals, Alarmins, and DAMPs

The host immune response has evolved over time to protect organisms from infection, injury, and subsequent death. Danger signals (22-24) are molecules that alert and activate the host immune response – these danger signals may come from either the internal or the external environments and activate cells of either the innate or adaptive immune response. External or exogenous danger signals have traditionally been called pathogen-associated molecular patterns (PAMPs) and include pathogen-derived proteins, nucleic acids, and lipids such as lipopolysaccharide (LPS), peptidoglycan, lipoteichoic acid, CpG DNA, and flagellin. These PAMPs are recognized by a surprisingly limited number of highly conserved pattern recognition receptors (PRRs), which include the Toll-like receptors (TLRs) and the nucleotide-binding oligomerization domain (NOD) receptors. Perhaps it is more than just a mere coincidence that these same PRR appear to recognize endogenous danger signals as well (25) – hence the term, danger-associated molecular pattern or DAMP (26). Endogenous danger signals may be secreted by damaged cells or released rather non-specifically by necrotic cells to act in an autocrine, paracrine, or endocrine manner, thereby alerting the host to the presence of tissue injury. Oppenheim was the first to coin the term *alarmin* for these endogenous DAMPs (27). In summary then, exogenous DAMPs (LPS, CpG DNA, etc) usually trigger an immune response to an infectious insult (e.g. bacteremia), while endogenous DAMPs or alarmins trigger an immune response to tissue injury, such as may occur with trauma, ischemia-reperfusion injury, oxidative stress, etc. Several candidate alarmins have been described, including high mobility group box 1 protein (HMGB1) (28-33), uric acid (34-39), and extracellular HSPs (6, 26, 33, 40-43), among others.

Several properties would suggest that extracellular HSPs are biologically plausible and likely candidates to serve as alarmins (44-46). First, collectively, the HSPs are the most abundant intracellular proteins, representing up to 10% of the total protein in the cell. For example, 1 g of tissue contains approximately 2.5 mg of HSPs. The lysis of 10^5 to 10^6 cells (approximately 1 mg) would result in the release of approximately 2 μ g HSP, translating to a local concentration of 1-2 mg/mL at the tissue level (47). Second, several of the HSPs are markedly induced (up to 15% of the total intracellular protein content) in response to a diverse range of cellular insults, including increased temperature, oxidative stress, glucose deprivation, chemical exposure, I/R injury, ultraviolet radiation, and infectious agents such as LPS. Third, HSPs are ancient, highly conserved molecules that have been identified in virtually every organism, both prokaryotic and eukaryotic, that have been examined to date. In comparison, LPS, an important “exogenous” danger signal, appeared relatively late on the evolutionary time-scale and is much less ubiquitous, being unique to only gram-negative bacteria. It is tempting to speculate that the programmed response to the exogenous “danger signal”, LPS, is modeled on the more primitive programmed response to the endogenous “danger signal” (47). Fourth, HSPs are highly immunomodulatory and have the capacity to mediate the induction of peptide-specific immunity. For example, as molecular chaperones, HSPs bind to many peptides derived from the cells from which they are isolated. HSP-peptide complexes elicit potent T cell responses against the chaperoned peptide as well as

the cell type from which the chaperoned peptide is derived, including tumors and viruses, and vaccination with HSP-tumor peptide complexes as an immunotherapy for cancer is an active area of investigation (44-45, 47-50). Similarly, HSP-pathogen-derived peptide complexes have the capacity to elicit a pathogen-specific immune response (45). Finally, HSPs themselves, especially members of the Hsp70 (HSPA) and Hsp60 (HSPD) families, have the capacity to activate the host innate immune response, resulting in dendritic cell activation and maturation, activation of complement, and release of proinflammatory cytokines (51-62).

Potential Mechanisms of Release of the Heat Shock Proteins

One argument that is frequently cited against the purported role for extracellular HSPs as endogenous danger signals has been the lack of any clearly defined mechanism to explain their release into the extracellular environment (63). Collectively, the HSPs lack the classic N-terminus leader sequence necessary for the canonical protein secretory pathway (64). Of interest, several additional proteins involved in the host immune response similarly lack the classic N-terminus leader sequence and are secreted through non-classical pathways (Table 2) (65). What many investigators fail to recognize, however, is that there are diverse secretory pathways utilized by both prokaryotic and eukaryotic organisms, many of which have only recently been elucidated (7, 66-69). While HSPs undoubtedly are released during necrotic cell death, most studies suggest that this is not the major mechanism of release (20, 64, 70-73). For example, several studies have shown that release of HSPs generally occurs in the absence of significant cell death (20, 64, 70-76). Perhaps the best evidence comes from an experiment in which serum Hsp72 (HSPA) concentrations were measured in Sprague-Dawley rats following exposure to a cat. Rats were physically separated from the cat using a clear Plexi-glass shield. In this experiment, cat exposure induced a significant increase in both corticosterone and extracellular Hsp72 (HSPA) production. This response was not observed in adrenalectomized rats (77). Finally, there are several studies demonstrating increased serum Hsp72 (HSPA) levels in patients following exercise (78-79). Collectively, these studies strongly suggest that HSP are released via a specific, though as yet undefined, secretory mechanism.

Hsp72 (HSPA) is perhaps the best and most widely studied extracellular heat shock protein and was first reported in cultured rat embryo cells following exposure to increased temperature in the late 1980's (80). The mechanism of release appeared to be specific, in that Hsp72 (HSPA) release could not be reproduced by induction of cell lysis through exposure to non-ionic detergents. However, the mechanism did not appear to involve classic secretory pathways either, as it was not inhibited by either colchicine or monensin, both of which inhibit this pathway. Finally, Hsp72 (HSPA) synthesized in the presence of a lysine amino acid analogue (aminoethyl cysteine) was not released from these cells, suggesting that the altered protein structure prevented interaction with an as yet unidentified, but specific secretory mechanism (80). Several groups, including ours (70, 80-86) have shown that viable cells release Hsp72 (HSPA) in a specific and inhibitable manner. Monensin and brefeldin A are inhibitors of the classic endoplasmic reticulum (ER)/Golgi protein transport and secretory pathways. We have shown that Hsp72 (HSPA) release from THP-1 cells is not inhibited by either monensin or brefeldin A (70). In this particular study, release of

extracellular Hsp72 (HSPA) was early and sustained up to 24 hours following heat shock and did not require new protein synthesis. Others have shown that Hsp72 (HSPA) release from peripheral blood monocytes (PBMC) is inhibited by brefeldin A, but not monensin (84, 86). Hsp72 (HSPA) release has also inhibited by methylamine and methyl- β -cyclodextrin, both of which inhibit protein secretion via lysosomal pathways (86). Recent studies suggest that Hsp72 (HSPA) is actively released via an exosome-dependent, non-classical protein secretory pathway (74, 76, 87).

The Immunomodulatory Effects of Extracellular Heat Shock Proteins

Heat shock protein 72 (HSPA)

Extracellular Hsp72 (HSPA) is a highly immunomodulatory protein with effects on both the innate and adaptive immune responses (6-7, 17). In this regard, extracellular Hsp72 (HSPA) appears to specifically interact with a wide myriad of cell surface receptors, including TLR2, TLR4, LOX-1, CD91, CD94 (C-type lectin), CD40 and chemokine receptor CCR5 (45-46, 61, 88-90). These studies have used a variety of approaches to demonstrate physical interactions between Hsp72 and the purported receptor protein and are reviewed further in an excellent discussion by Binder and colleagues (91). Hsp72 (HSPA), consistent with its role as a “chaperokine” appears to stimulate pro-inflammatory gene expression in macrophage and monocyte cell lines via both TLR-2 and TLR-4 (51, 53-54). In addition, we have shown that extracellular Hsp72 (HSPA) stimulates pro-inflammatory gene expression in cultured bronchial epithelial cells (92), hepatocytes (93), neutrophils (71), and cardiomyocytes (*Wheeler, unpublished data*). Moreover, intratracheal administration of extracellular Hsp72 (HSPA) induced pro-inflammatory gene expression in mice, primarily through TLR4 and NF- κ B activation (92). Our group has also demonstrated that extracellular Hsp72 (HSPA) induces the endotoxin tolerance phenotype in THP-1 cells. Preconditioning with low-dose Hsp72 (HSPA) reprogrammed the subsequent response to LPS, such that LPS-mediated TNF- α gene expression was markedly abrogated (70, 94). Subsequent experiments have demonstrated that these effects are not exclusive to TLR4 ligands, but that Hsp72 (HSPA) preconditioning also reprograms the response to TLR2 ligands, such as Pam3CysK, lipoteichoic acid, peptidoglycan, heat-killed *Staphylococcus aureus* (HKSA), and Hsp72 (HSPA) itself (*Wheeler, unpublished data*).

Some of the immunomodulatory effects of extracellular Hsp72 (HSPA) and other heat shock proteins have been ascribed to the presence of bacterial contaminants in the recombinant protein (95-100). However, extensive and elegantly performed experimental controls strongly suggest that it is indeed the heat shock protein itself that is responsible for these effects. Typically, these controls include (i) measuring the LPS content of the recombinant protein via *Limulus* amoebocyte lysate assay (LAL) and adding this concentration to control; (ii) directly inhibiting LPS activity with concomitant treatment with polymyxin B, lipid A, or lipid IVa treatment; (iii) heat denaturation or trypsin pretreatment of the recombinant protein to confirm loss of immunomodulatory activity; and (iv) comparing immunomodulatory activity of the recombinant protein to irrelevant polypeptide sequences or similar sized proteins (101). In addition, Hsp72 (HSPA) purified from liver cell lysates induced secretion of IL-1 β , TNF- α , and IL-12 by murine macrophages (52). Similarly, we

have shown that endogenously released Hsp72 (HSPA) induces cellular reprogramming in THP-1 cells (70). Neutralizing antibodies directed against extracellular Hsp72 (HSPA) have been shown to inhibit these pro-inflammatory effects (29). Finally, an important consideration is whether extracellular Hsp72 (HSPA) chaperones small amounts of LPS and other PAMPs to their respective cell surface receptors, thereby augmenting stimulation of the innate immune response (101). With this in mind, the effects of Hsp72 (HSPA) on the innate immune response in the absence of bacterial contaminants may be moot.

Extracellular Hsp72 (HSPA) has additional effects on the innate immune response. For example, extracellular Hsp72 (HSPA) both directly (102-103) and indirectly (by stimulating increased chemokine synthesis) (71, 92) induces neutrophil and dendritic cell chemotaxis. In addition, extracellular Hsp72 (HSPA) appears to play an important role in priming dendritic cells, macrophages, monocytes, and natural killer cells (40, 46, 63, 101). To this end, extracellular Hsp72 (HSPA) enhances synthesis of pro-inflammatory cytokines and upregulates cell surface expression of MHC class II and other important co-stimulatory molecules on dendritic cells (51, 53-56). Extracellular Hsp72 (HSPA) also directly stimulates macrophage phagocytic activity (104-106). Extracellular Hsp72 (HSPA) induces natural killer (NK) cell activity (107-110). NK cells play an important role in both the innate and adaptive immune responses. These unique cells exert cytotoxicity through both direct effects (via perforin production) and via mediation of antibody-dependent cytotoxicity.

Extracellular Hsp72 (HSPA) also exerts important effects on the adaptive immune response. For example, Hsp72 is able to chaperone a large variety of immunomodulatory peptides derived from tumors, virally-infected cells, etc and deliver them to antigen presenting cells. These chaperone/peptide complexes subsequently generate peptide-specific T-lymphocyte-mediated responses both *in vitro* and *in vivo*. Several groups are currently attempting to exploit this unique facet of heat shock protein biology for vaccine development and cancer immunotherapy (40, 46, 49, 111-113).

A few studies have been able to demonstrate uptake of extracellular Hsp72 (HSPA). More importantly, uptake of extracellular Hsp72 (HSPA) appears to confer some degree of stress tolerance (85, 114-117). While the data are far from complete, these studies at least suggest a potential autocrine or paracrine role for extracellular Hsp72 (HSPA), further supporting the concept that heat shock proteins are endogenous danger signals or alarmins.

Extracellular Hsp72 (HSPA) has been found in the blood, cerebrospinal fluid, and bronchoalveolar lavage fluid of critically ill children and adults with a variety of inflammatory disease states. For example, increased extracellular Hsp72 levels following cardiopulmonary bypass have been detected in both adults (118-119) and children (*Wheeler, unpublished data*). Increased extracellular Hsp72 (HSPA) levels correlate with poor outcome in critically ill patients with liver disease (120), coronary artery disease (121-124), pre-eclampsia (125), sickle cell disease vaso-occlusive crisis (126), diabetic ketoacidosis (127), and septic shock (128). Extracellular Hsp72 (HSPA) levels in the cerebrospinal fluid (CSF) of children with traumatic brain injury also appear to correlate with poor outcome (129). Finally, extracellular Hsp72 (HSPA) has been found in the pulmonary edema fluid of adults with acute lung injury (130) and the urine of children following renal transplantation

(131). Given the signaling properties recently ascribed to Hsp72 (HSPA), these data suggest that the release of Hsp72 (HSPA) could potentiate an already active host immune response, thereby leading to poor outcome (132). Alternatively, extracellular Hsp72 (HSPA) could serve an as yet undefined cytoprotective function at lower levels as a normal response to infection or stress, and once a certain critical threshold is attained, it could potentiate the dysregulated inflammatory response that subsequently results in multiple organ failure. Recent experimental data (133) and the finding that extracellular Hsp72 (HSPA) levels > 15 ng/mL correlated with improved outcome following multiple trauma in adults (134) support this concept. As such, it is tempting to speculate that lower levels of extracellular Hsp72 (HSPA) “cool down” the host inflammatory response, while higher levels further stimulate and/or augment the host inflammatory response. These important questions remain an active focus of investigation in many laboratories, including our own.

Hsp27 (HSPB1)

Hsp27 (HSPB1) is a member of the so-called small heat shock protein family (HSPB). Within quiescent cells, it assists in the degradation and removal of damaged proteins and also slows the rate of actin microfilament polymerization (135). Like several members of the heat shock protein family, Hsp27 (HSPB1) is highly stress inducible. Following cell stress, Hsp27 (HSPB1) is phosphorylated and loses the ability to slow the rate of actin polymerization, resulting in stabilization of the cellular cytoskeleton. Additionally, Hsp27 (HSPB1) has been shown to protect cells against apoptosis through the prevention of downstream caspase activation (136).

Hsp27 (HSPB1) is released from peripheral blood monocytes following treatment with TNF- α (137). Extracellular Hsp27 (HSPB1) appears to possess anti-inflammatory properties, with the target cell type determining the functionality. However, the receptor through which extracellular Hsp27 (HSPB1) inhibits inflammation is as yet poorly defined. Hsp27 (HSPB1) inhibits neutrophil apoptosis and potentially allows for exaggerated tissue destruction during sepsis, trauma, and acute lung injury (138). In stark contrast to the exogenous danger signal, LPS, Hsp27 (HSPB1) inhibits neutrophil apoptosis without increasing pro-inflammatory cytokine production (138). Hsp27 (HSPB1) induces expression of the anti-inflammatory cytokine, IL-10, in monocytes, primarily through the p38 protein kinase pathway, with only a mild increase in TNF- α levels (139-140). Hsp27 (HSPB1) also inhibits monocyte differentiation into mature dendritic cells or macrophages (141).

These anti-inflammatory effects may be exploited by tumor cells, as the dampening of the host immune response may allow tumor progression and metastasis (142). For example, increased serum levels of Hsp27 (HSPB1) have been associated with worse outcome in women with breast, ovarian, and uterine cancer (143). In contrast, antibodies to Hsp27 (HSPB1) have been identified in the blood of women with breast cancer and other gynecologic cancers (144-145). Those women with the highest levels of anti-Hsp27 serum antibodies seemed to have improved breast cancer survival (146). Increased tumor expression of Hsp27 (HSPB1) is associated with shorter cancer free periods and advanced cancer staging, possibly due to the inhibition of tumor cell apoptosis (147). Other studies have contradicted these findings, with no demonstrated association between serum Hsp27

(HSPB1) levels and cancer survival (147-148). Hsp27 (HSPB1) also appears to be released from some brain tumor cells to dampen the immune response, inhibit apoptosis, and allow for tumor growth, progression, and metastasis (149). The anti-inflammatory properties of Hsp27 (HSPB1) may be potentially exploited for the treatment of inflammatory disease processes. For example, Hsp27 (HSPB1) administration improves motor neuron survival for up to one week following nerve transection in neonatal mice (150).

In addition to playing a role in tumor growth and progression, extracellular Hsp27 (HSPB1) appears to play a role in the pathophysiology of cardiovascular disease. For example, Hsp27 (HSPB1) blocks lipid uptake by competitive inhibition of a low-density lipoprotein (LDL) scavenger receptor-A and decreases atherosclerotic plaque formation *in vitro* (140). Clinically, extracellular Hsp27 (HSPB1) levels may be a reasonable biomarker for atherosclerosis disease progression (151-152). Several studies have demonstrated an inverse association between Hsp27 (HSPB1) levels and atherosclerosis (151, 153-155). However, a prospective study of 255 healthy women showed an inverse association with age but not serum Hsp27 (HSPB1) levels and future major cardiovascular events (154).

Higher levels of Hsp27 (HSPB1) have also been shown to protect mouse hearts from reperfusion injury and myocardial infarction(156). In a small adult study, the expression of Hsp27 in transplanted hearts in acute rejection was elevated and thought to be a self-protective mechanism(157). Further corroborating this theory, the vessels of transplanted hearts with higher phosphorylated levels of Hsp27 (HSPB1) upon biopsy demonstrated less cardiac allograft vasculopathy when compared to transplanted heart vessels with vasculopathy (158). Similarly, and perhaps more relevant to the present discussion, there have been a few studies showing that elevated levels of Hsp27 (HSPB1) and/or decreased levels of autoantibodies to Hsp27 (HSPB1) correlate with improved outcome in patients with acute coronary syndrome (153, 159-160).

Hsp90 (HSPC)

Hsp90 (HSPC) is one of the most abundant proteins inside the cell. Hsp90 (HSPC) plays an important role in maintaining normal homeostasis and acts as a scaffolding protein for several key enzyme and signal transduction systems (161-163). So far, however, there have been comparatively few reports describing Hsp90 (HSPC) in the extracellular environment. We have shown that increased plasma Hsp90 (HSPC) levels correlate with worse outcome in critically ill children with septic shock (*Wheeler, unpublished data*). In addition, extracellular Hsp90 (HSPC) induces IL-8 gene expression in cultured vascular smooth muscle cells in a TLR4- and NF-B-dependent manner (164). Finally, a human recombinant antibody directed against yeast-derived Hsp90 (HSPC) has been used to treat critically ill patients with invasive candidiasis . In this study, recombinant antibody to Hsp90 plus lipid-associated amphotericin B produced significant clinical and culture-confirmed improvement in outcome for patients with invasive candidiasis (165-168). Given these data, it is very likely that future studies will demonstrate functional roles for extracellular Hsp90 (HSPC).

Hsp60 (HSPD)

Hsp60 (HSPD) is a key mitochondrial chaperone that forms a complex with the chaperonin (Cpn)/Hsp10 (HSPE) (169-170). Extracellular human Hsp60 (HSPD) appears to be involved in many autoimmune and inflammatory processes within the body. Some of these processes are thought to be triggered by a number of infectious agents through molecular mimicry, in which the initial host immune response to microbial-derived Hsp60 (HSPD) leads to a subsequent cross reaction to the host-derived Hsp60 (HSPD). For example, both *Chlamydia pneumoniae* Hsp60 (HSPD) and the host human Hsp60 (HSPD) have been detected in atheromas (171). Both of these molecules were shown to have the ability to activate host macrophages and endothelial cells contributing to the progression of atherosclerosis (171). For the purposes of this review however, only research involving isolated human Hsp60 will be discussed.

Circulating antibodies to human Hsp60 (HSPD) appear to play a role in the pathophysiology of a number of vasculopathies and related illnesses. For example, in an animal model of atherosclerosis, auto-antibodies to Hsp60 were shown to be involved in disease progression (172). Increased circulating levels of anti-Hsp60 (HSPD) antibodies have been found in patients with carotid artery atherosclerosis (173). Elevated Hsp60 (HSPD) antibodies were also found in patients with other vasculopathies, such as borderline hypertension (174). Increased circulating anti-Hsp60 (HSPD) antibody titers have also been found in patients with coronary artery disease (175) and correlate with the presence and severity of disease after adjusting for traditional risk factors (176). Interestingly, the antibody titers in coronary artery disease patients decreased after an acute myocardial infarction (175). The authors speculated that a soluble form of Hsp60 (HSPD) must be released from the ischemic myocardial tissue to complex with the anti-Hsp60 (HSPD) antibodies (175). This hypothesis was confirmed by several independent groups showing increased levels of Hsp60 (HSPD) following acute myocardial infarction (177-178). Similarly, increased circulating levels of both Hsp60 (HSPD) and anti-Hsp60 antibodies have been associated with an increased risk of developing coronary artery disease (178) and appear to correlate with increased severity of disease, even controlling for all other risk factors (179). In a follow-up surveillance study enrolling healthy civil service workers, increased plasma Hsp60 (HSPD) levels correlated with increased plasma TNF- α , psychological distress (primarily in women), low socioeconomic status, and social isolation (180), resulting in an increased propensity for coronary artery disease.

Xu and colleagues discovered an association between elevated circulating levels of Hsp60 (HSPD) and the progression and severity of carotid artery atherosclerosis (181). This association was further investigated prospectively. Patients with a sustained elevation of serum Hsp60 (HSPD) were found to be at risk for the development of early atherosclerosis (182). High levels were also found in patients with borderline hypertension which was again associated with the development of early cardiovascular disease (183). However, when Hsp60 (HSPD) was measured in patients with chronic hypertension and chronic vascular disease, these levels were found to be similar to healthy controls (121, 184), potentially suggesting increased binding to anti-Hsp60 (HSPD) antibodies.

Extracellular Hsp60 (HSPD) plays a role in the pathophysiology of many autoimmune diseases (185). For example, elevated IgG antibodies to Hsp60 (HSPD) are found in the sera of patients with rheumatic autoimmune diseases (186). Host-derived Hsp60 (HSPD) appears to play a role in the regulation of autoimmune arthritis in rats (187-188). An antigen-specific T-cell response to Hsp60 (HSPD) was associated with improved outcome in patients with juvenile idiopathic arthritis (JIA) (189-190), possibly through increased IL-10 production by regulatory T-cells (191). Armed with this data, vaccines against Hsp60 (HSPD) have shown promising results in models of arthritis and cyclophosphamide-accelerated diabetes (192-194).

It is becoming clearer that extracellular Hsp60 (HSPD) plays a role in inflammation and the body's immune response. To this end, we have shown that increased circulating Hsp60 (HSPD) levels correlates with poor outcome in critically ill children with septic shock (195). Similar to extracellular Hsp72 (HSPA), Hsp60 (HSPD) appears to act primarily via the TLR4 pathway (196-197), though activation of the TLR2 pathway has also been observed (196). Hsp60 (HSPD) activates human macrophages and dendritic cells to produce Th1 inflammatory cytokines such as TNF α and interferon (IFN)- γ (198-199). However, determining the specific cytokine profile may be dose dependent as both Th1 and Th2 cytokine profiles resulted when dendritic cells were treated with lower concentrations of Hsp60 (HSPD) (199). Similar to LPS and extracellular Hsp72 (HSPA), Hsp60 (HSPD) may also be able to promote inflammation initially and then induce a state of tolerance (200-201), akin to the endotoxin tolerance phenotype. Again, the potential effects of contamination of the recombinant Hsp60 (HSPD) protein with bacterial products must be considered and assessed with the use of adequate controls (see discussion above).

Hsp60 (HSPD) also appears to activate the adaptive immune response. For example, Hsp60 (HSPD) can inhibit pro-inflammatory cytokine production and shift to an anti-inflammatory Th2 profile in T lymphocytes (202). However, other studies have shown that Hsp60 (HSPD) increases IFN- γ production in T lymphocytes (203). Similarly, extracellular Hsp60 (HSPD) has been shown to activate B-cells in a mixed Th1 and Th2 manner with B-cells producing both IFN- γ and IL-10 (204).

Chaperonin (Cpn)/Hsp10 (HSPE)

As discussed briefly above, Cpn/Hsp10 (HSPE) was the first heat shock protein to be isolated outside the cell. In this case, Cpn/Hsp10 (HSPE) was isolated from the serum of pregnant females as early pregnancy factor (EPF) (19, 205). EPF was originally believed to be essential for the initiation and maintenance of the developing embryo during early pregnancy and was later found to be homologous to rat Cpn/Hsp10 (HSPE). EPF appears to have growth factor qualities (206), as well as anti-inflammatory properties which are necessary for protecting the embryo from the mother's own immune system (207-208). Cpn/Hsp10 (HSPE) is released into circulation by dividing primitive cancer cells (206). Cpn/Hsp10 (HSPE) forms a complex with the mitochondrial co-chaperone, Hsp60 (HSPD) and assists with the proper folding of mitochondrial proteins, as well as the reactivation of denatured proteins(170).

Relevant to the present discussion, Cpn/Hsp10 (HSPE) appears to modulate the innate immune system through interactions with monocytes, lymphocytes, and natural killer cells (208). Disease specific animal models have produced compelling data describing the immunosuppressive activities of Cpn/Hsp10 (HSPE). For example, it was shown to decrease the expression of leukocyte trafficking adhesion molecules and the immune response in an animal model of multiple sclerosis and delayed-type hypersensitivity (209). The inflammatory response was also suppressed in animal models of allograft transplantation, resulting in increased graft survival (210-211). The *in vitro* administration of recombinant Cpn/Hsp10 (HSPE) appeared to inhibit LPS-induced NF- κ B activation, thereby decreasing inflammatory cytokine and chemokine production, as well (211).

Extracellular Heat Shock Proteins and Sepsis

Our understanding of the relative contribution of intracellular versus extracellular HSPs in the pathophysiology of the sepsis syndrome is far from complete. For example, numerous *in vitro* and *in vivo* studies suggest that augmenting the intracellular expression of HSPs is beneficial to the host (5-7, 17, 212-213). Indeed, the discovery of innovative methods of augmenting intracellular HSP expression in the clinical setting remains an active area of focus for several laboratories, including our own. On the other hand, there is compelling evidence that extracellular HSPs augment the host innate and adaptive immune response (discussed above). The immunomodulatory effects (i.e. either stimulatory or inhibitory) of extracellular HSPs are largely dependent upon contextual factors. Rather than viewing intracellular and extracellular HSP expression as two independent and mutually exclusive processes, we hypothesize that moderate levels of stress, such that would occur in critically ill patients with sepsis, increase both intracellular HSP expression and extracellular release of HSP, likely through some as yet undefined active, secretory mechanism. These two events result in enhanced protection for both the host cell, as well as cells in the immediate surroundings through either active uptake (and enhanced protection through increased intracellular HSP expression) or activation of stress response programs. Conversely, greater levels of stress further augment intracellular HSP expression and cause necrotic cell death, resulting in the release of large quantities of HSPs and causing an overzealous activation of the host inflammatory response through their immunostimulatory effects.

Conclusion

The stress response is characterized by a rapid increase in both the intracellular expression and subsequent release of a unique group of proteins, known as heat shock proteins. While intracellular HSPs predominantly down-regulate the host inflammatory response, extracellular HSPs may increase or decrease the host inflammatory response. The extracellular HSPs are now included in a growing list of so-called danger-associated molecular patterns (DAMPs), or alarmins. Further studies are necessary to better characterize the effects of these special proteins on the host inflammatory response during sepsis.

Acknowledgments

Supported by the National Institutes of Health, K08GM077432 (DSW), R03HD058246 (DSW)

References

1. De Maio A. The heat-shock response. *New Horiz.* 1995; 3:198–207. [PubMed: 7583161]
2. De Maio A. Heat shock proteins: Facts, thoughts, and dreams. *Shock.* 1999; 11:1–12. [PubMed: 9921710]
3. Ritossa F. A new puffing pattern induced by temperature shock and DNP in *Drosophila*. *Experientia.* 1962; 18:571–3.
4. Ritossa F. Discovery of the heat shock response. *Cell Stress Chaperones.* 1996; 1:97–8. [PubMed: 9222594]
5. Wong HR, Wispe JR. The stress response and the lung. *Am J Physiol.* 1997; 273:L1–L9. [PubMed: 9252533]
6. Wheeler DS, Wong HR. Heat shock response and acute lung injury. *Free Radic Biol Med.* 2007; 42:1–14. [PubMed: 17157189]
7. Wheeler, DS.; Zingarelli, B.; Wong, HR. The role of extracellular heat shock proteins in cellular inflammation and injury. Vincent, J-L., editor. Springer-Verlag; Berlin, Germany: 2006.
8. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford EA, et al. Guidelines for the nomenclature of the human heat shock proteins. *Cell Stress Chaperones.* 2009; 14:105–11. [PubMed: 18663603]
9. Wong HR, Odoms K, Sakthivel B. Divergence of canonical danger signals: The genome-level expression patterns of human mononuclear cells subjected to heat shock or lipopolysaccharide. *BMC Immunol.* 2008; 9:24. [PubMed: 18510776]
10. Sonna LA, Hawkins L, Lissauer ME, Maldeis P, Towns M, Johnson SD, et al. Core temperature correlates with expression of selected stress and immunomodulatory genes in febrile patients with sepsis and noninfectious SIRS. *Cell Stress Chaperones.* 2010; 15:55–66. [PubMed: 19496026]
11. Bond U, Schlesinger MJ. Ubiquitin is a heat shock protein in chicken embryo fibroblasts. *Mol Cell Biol.* 1985; 5:949–56. [PubMed: 2987683]
12. Muller-Taubenberger A, Hagmann J, Noegel A, Gerisch G. Ubiquitin gene expression in *Dictyostelium* is induced by heat and cold shock, cadmium, and inhibitors of protein synthesis. *J Cell Sci.* 1988; 90:51–8. [PubMed: 2848853]
13. Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. *Mol Cell Biochem.* May-Jun;2002 234-235(1-2): 249–63. [PubMed: 12162441]
14. Dunsmore KE, Denenberg AG, Page K, Wong HR. Mechanism and function of heat shock-dependent IkappaBalpha expression. *Inflamm Res.* 2006; 55:254–9. [PubMed: 16955245]
15. Harris MB, Blackstone MA, Ju H, Venema VJ, Venema RC. Heat-induced increases in endothelial NO synthase expression and activity and endothelial NO release. *Am J Physiol Heart Circ Physiol.* 2003; 285:H333–H40. [PubMed: 12663266]
16. Wong HR, Dunsmore K, Page K, Shanley TP. Heat shock-mediated regulation of MKP-1. *Am J Physiol Cell Physiol.* 2005; 289:C1152–C8. [PubMed: 15958526]
17. Wheeler, DS.; Wong, HR. The heat shock response and transplantation immunology. Wilkes, DS.; Burlingham, WD., editors. Kluwer Academic/Plenum Publishers; New York: 2004.
18. Morton H, Rolfe B, Clunie GJ. An early pregnancy factor detected in human serum by the rosette inhibition test. *Lancet.* 1977; 1:394–7. [PubMed: 65512]
19. Cavanagh AC, Morton H. The purification of early-pregnancy factor to homogeneity from human platelets and identification as chaperonin 10. *Eur J Biochem.* Jun 1; 1994 222(2):551–60. [PubMed: 7912672]
20. Hightower LE, Guidon PTJ. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. *J Cell Physiol.* 1989; 138:257–66. [PubMed: 2918030]
21. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. *Trends Immunol.* Mar; 2002 23(3):130–5. [PubMed: 11864840]
22. Matzinger P. An innate sense of danger. *Semin Immunol.* 1998; 10:399–415. [PubMed: 9840976]

23. Jerome KR, Corey L. The danger within. *N Engl J Med*. 2004; 350:411–2. [PubMed: 14736935]
24. Skoberne M, Beignon AS, Bhardwaj N. Danger signals: A time and space continuum. *Trends Mol Med*. 2004; 10:251–7. [PubMed: 15177188]
25. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. *Shock*. 2006; 26:430–7. [PubMed: 17047512]
26. Bianchi ME. DAMPs, PAMPs, and alarmins: All we need to know about danger. *J Leukocyte Biol*. 2007; 81:1–5. [PubMed: 17032697]
27. Oppenheim JJ, Yang D. Alarmins: Chemotactic activators of immune responses. *Curr Opin Immunol*. 2005; 17:359–65. [PubMed: 15955682]
28. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. *J Leukocyte Biol*. 2007; 81:59–66. [PubMed: 16966386]
29. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. *Immunol Lett*. 2007; 111:36–44. [PubMed: 17568691]
30. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. *J Cell Biol*. 2007; 179:33–40. [PubMed: 17923528]
31. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. *Mol Med*. 2008; 14:476–84. [PubMed: 18431461]
32. Klune JR, Billiar TR, Tsung A. HMGB1 preconditioning: Therapeutic application for a danger signal? *J Leukocyte Biol*. 2008; 83:558–63. [PubMed: 17938274]
33. Williams JH, Ireland HE. Sensing danger - Hsp72 and HMGB1 as candidate signals. *J Leukocyte Biol*. 2008; 83:489–92. [PubMed: 18156188]
34. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alters the immune system to dying cells. *Nature*. 2003; 425:516–21. [PubMed: 14520412]
35. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature*. 2006; 440:237–41. [PubMed: 16407889]
36. Zare F, Magnusson M, Bergstrom T, Brisslert M, Josefsson E, Karlsson A, et al. Uric acid, a nucleic acid degradation product, down-regulates dsRNA-triggered arthritis. *J Leukocyte Biol*. 2006; 79:482–8. [PubMed: 16387838]
37. Liu K, Inoue H, Nakayama H, Kanno R, Kanno M. The endogenous danger signal uric acid augments contact hypersensitivity responses in mice. *Pathobiology*. 2007; 74:177–85. [PubMed: 17643063]
38. Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempsi J, et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. *Blood*. 2008; 111:1472–9. [PubMed: 18029553]
39. Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. *Am J Respir Crit Care Med*. 2009; 179:903–13. [PubMed: 19218193]
40. Calderwood SK, Mambula SS, Gray PJJ. Extracellular heat shock proteins in cell signaling and immunity. *Ann N Y Acad Sci*. 2007; 1113:28–39. [PubMed: 17978280]
41. Calderwood SK, Mambula SS, Gray PJJ, Theriault JR. Extracellular heat shock proteins in cell signaling. *FEBS Lett*. 2007; 581:3689–94. [PubMed: 17499247]
42. Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. *Curr Opin Crit Care*. 2006; 12:595–601. [PubMed: 17077693]
43. Kaczorowski DJ, Mollen KP, Edmonds R, Billiar TR. Early events in the recognition of danger signals after tissue injury. *J Leukocyte Biol*. 2008; 83:546–52. [PubMed: 18032691]
44. Pockley AG. Heat shock proteins in health and disease: Therapeutic targets or therapeutic agents? *Expert Rev Mol Med*. 2001; 2001:1–21. [PubMed: 14585147]
45. Pockley AG. Heat shock proteins as regulators of the immune response. *Lancet*. 2003; 362:469–76. [PubMed: 12927437]

46. Pockley AG, Muthana M, Calderwood SK. The dual immunoregulatory roles of stress proteins. *Trends Biochem Sci.* 2008; 33:71–9. [PubMed: 18182297]
47. Anderson KM, Srivastava PK. Heat, heat shock, heat shock proteins and death: A central link in innate and adaptive immune responses. *Immunol Lett.* 2000; 74:35–9. [PubMed: 10996625]
48. Robert J. Evolution of heat shock protein and immunity. *Dev Comp Immunol.* Jun-Jul;2003 27(6-7):449–64. [PubMed: 12697304]
49. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. *Science.* 1997; 278:117–20. [PubMed: 9311915]
50. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. *Immunity.* 1998; 8:657–65. [PubMed: 9655479]
51. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. *Nat Med.* Apr; 2000 6(4):435–42. [PubMed: 10742151]
52. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappaB pathway. *Int Immunol.* 2000; 12:1539–46. [PubMed: 11058573]
53. Asea A, Kabingu E, Stevenson MA, Calderwood SK. HSP70 peptide-bearing and peptide-negative preparations act as chaperokines. *Cell Stress Chaperones.* 2000; 5:425–31. [PubMed: 11189447]
54. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. *J Biol Chem.* Apr 26; 2002 277(17):15028–34. [PubMed: 11836257]
55. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/Interleukin-1 receptor signal pathway. *J Biol Chem.* 2002; 277:15107–12. [PubMed: 11842086]
56. Bethke K, Staib F, Distler M, Schmitt U, Jonuleit H, Enk AH, et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. *J Immunol.* Dec 1; 2002 169(11):6141–8. [PubMed: 12444117]
57. Panjwani NN, Popova L, Srivastava PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. *J Immunol.* 2002; 168:2997–3003. [PubMed: 11884472]
58. Prohaszka Z, Singh M, Nagy K, Kiss E, Lakos G, Duba J, et al. Heat shock protein 70 is a potent activator of the human complement system. *Cell Stress Chaperones.* Jan; 2002 7(1):17–22. [PubMed: 11892984]
59. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. *Blood.* 2002; 100:4108–15. [PubMed: 12393401]
60. Radsak MP, Hilf N, Singh-Jasuja H, Braedel S, Brossart P, Rammensee H-G, et al. The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. *Blood.* 2003; 101:2810–5. [PubMed: 12446445]
61. Campisi J, Leem TH, Fleshner M. Stress-induced extracellular Hsp72 is a functionally significant danger signal to the immune system. *Cell Stress Chaperones.* 2003; 8:272–86. [PubMed: 14984061]
62. Tsan M-F, Gao B. Endogenous ligands of Toll-like receptors. *J Leukoc Biol.* 2004; 76:514–9. [PubMed: 15178705]
63. Henderson B, Henderson S. Unfolding the relationship between secreted molecular chaperones and macrophage activation states. *Cell Stress Chaperones.* 2009; 14:329–41. [PubMed: 18958583]
64. Mambula SS, Stevenson MA, Ogawa K, Calderwood SK. Mechanisms for Hsp70 secretion: Crossing membranes without a leader. *Methods.* 2007; 43:168–75. [PubMed: 17920512]
65. Chimini, G.; Rubartelli, A. Novel pathways of protein secretion. In: Henderson, B.; Pockley, AG., editors. *Molecular Chaperones and Cell Signaling.* Cambridge University Press; New York: 2005. p. 45-60.
66. Prudovsky I, Mandinova A, Soldi R, Bagala C, Graziani I, Landriscina M, et al. The non-classical export routes: FGF1 and IL-1alpha point the way. *J Cell Sci.* 2003; 116:4871–81. [PubMed: 14625381]

67. Prudovsky I, Tarantini F, Landriscina M, Neivandt D, Soldi R, Kirov A, et al. Secretion without Golgi. *J Cell Biochem.* 2008; 103:1327–43. [PubMed: 17786931]
68. Nickel W, Seedorf M. Unconventional mechanisms of protein transport to the cell surface of eukaryotic cells. *Annu Rev Cell Dev Biol.* 2008; 24:287–308. [PubMed: 18590485]
69. Cascales E. The type VI secretion toolkit. *EMBO Rep.* 2008; 9:735–41. [PubMed: 18617888]
70. Abboud PA, Lahni PM, Page K, Giuliano JSJ, Harmon K, Dunsmore KE, et al. The role of endogenously produced extracellular hsp72 in mononuclear cell reprogramming. *Shock.* 2008; 30:285–92. [PubMed: 18323737]
71. Wheeler DS, Chase MA, Senft AP, Poynter SE, Wong HR, Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. *Respir Res.* 2009; 10:31. [PubMed: 19405961]
72. Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. *J Immunol.* 2006; 177:7849–57. [PubMed: 17114456]
73. Mambula SS, Calderwood SK. Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. *Int J Hyperthermia.* 2006; 22:575–85. [PubMed: 17079215]
74. Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: A novel secretory pathway for cellular stress proteins. *J Biol Chem.* 2005; 280:23349–55. [PubMed: 15826944]
75. Hunter-Lavin C, Davies EL, Bacelar MM, Marshall MJ, Andrew SM, Williams JH. Hsp70 release from peripheral blood mononuclear cells. *Biochem Biophys Res Commun.* 2004; 324:511–7. [PubMed: 15474457]
76. Vega VL, Rodriguez-Silva M, Frey T, Gehrmann M, Diaz JC, Steinem C, et al. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. *J Immunol.* 2008; 180:4299–307. [PubMed: 18322243]
77. Fleshner M, Campisi J, Amiri L, Diamond DM. Cat exposure induces both intra- and extracellular Hsp72: The role of adrenal hormones. *Psychoneuroendocrinology.* 2004; 29:1142–52. [PubMed: 15219638]
78. Lancaster GI, Febbraio MA. Mechanisms of stress-induced cellular HSP72 release: Implications for exercise-induced increases in extracellular HSP72. *Exerc Immunol Rev.* 2005; 11:46–52. [PubMed: 16385843]
79. Whitham M, Fortes MB. Heat shock protein 72: Release and biological significance during exercise. *Front Biosci.* 2008; 13:1328–39. [PubMed: 17981633]
80. Hightower LE, Guidon PT Jr. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. *J Cell Physiol.* 1989; 138:257–66. [PubMed: 2918030]
81. Barreto A, Gonzalez JM, Kabingu E, Asea A, Fiorentino S. Stress-induced release of HSC70 from human tumors. *Cell Immunol.* 2003; 222:97–104. [PubMed: 12826079]
82. Febbraio MA, Steensberg A, Walsh R, Koukoulas I, van Hall G, Saltin B, et al. Reduced glycogen availability is associated with an elevation in HSP72 in contracting skeletal muscle. *J Physiol.* 2002; 538:911–7. [PubMed: 11826174]
83. Lancaster GI, Moller K, Nielsen B, Secher NH, Febbraio MA, Nybo L. Exercise induces the release of heat shock protein 72 from the brain in vivo. *Cell Stress Chaperones.* 2004; 9:276–80. [PubMed: 15544165]
84. Ernani FP, Teale JM. Release of stress proteins from *Mesocricetus auratus* is a brefeldin A-inhibitable process: evidence for active export of stress proteins. *Infect Immun.* Jun; 1993 61(6): 2596–601. [PubMed: 8500897]
85. Guzhovala I, Kislyakova K, Moskaliyova O, Fridlanskaya I, Tytell M, Cheetham M, et al. In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. *Brain Res.* Sep 28; 2001 914(1-2):66–73. [PubMed: 11578598]
86. Hunter-Lavin C, Davies EL, Bacelar MMFVG, Marshall MJ, Andrew SM, Williams JHH. Hsp70 release from peripheral blood mononuclear cells. *Biochem Biophys Res Commun.* 2004; 324:511–7. [PubMed: 15474457]

87. Bausero M, Gastpar R, Multhoff G, Asea A. Alternative mechanism by which IFN-gamma enhances tumor recognition: Active release of heat shock protein 72. *J Immunol.* 2005; 175:2900–12. [PubMed: 16116176]
88. Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A, et al. Heat shock protein 70: Role in antigen presentation and immune stimulation. *Int J Hyperthermia.* 2002; 18:563–75. [PubMed: 12537755]
89. Todryk SM, Gough MJ, Pockley AG. Facets of heat shock protein 70 show immunotherapeutic potential. *Immunology.* 2003; 110:1–9. [PubMed: 12941135]
90. Johnson JD, Fleshner M. Releasing signals, secretory pathways, and immune function of endogenous extracellular heat shock protein 72. *J Leukoc Biol.* 2006; 79:425–34. [PubMed: 16387837]
91. Binder RJ, Vatner R, Srivastava P. The heat-shock protein receptors: Some answers and more questions. *Tissue Antigens.* 2004; 64:442–51. [PubMed: 15361121]
92. Chase MA, Wheeler DS, Lierl KM, Hughes VS, Wong HR, Page K. Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4 and NF-kappaB-dependent mechanisms. *J Immunol.* 2007; 179:6318–24. [PubMed: 17947709]
93. Galloway E, Shin T, Huber N, Eismann T, Kuboki S, Schuster R, et al. Activation of hepatocytes by extracellular heat shock protein 72. *Am J Physiol Cell Physiol.* 2008; 295:C514–C20. [PubMed: 18508912]
94. Aneja R, Odoms K, Dunsmore K, Shanley TP, Wong HR. Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. *J Immunol.* 2006; 177:7184–92. [PubMed: 17082636]
95. Gao B, Tsan M-F. Endotoxin contamination in recombinant human heat shock protein (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. *J Biol Chem.* 2003; 278:174–9. [PubMed: 12403778]
96. Gao B, Tsan M-F. Recombinant human heat shock protein 60 does not induce the release of tumor necrosis factor alpha from murine macrophages. *J Biol Chem.* 2003; 278:22523–9. [PubMed: 12686536]
97. Gao B, Tsan M-F. Induction of cytokines by heat shock proteins and endotoxin in murine macrophages. *Biochem Biophys Res Commun.* 2004; 317:1149–54. [PubMed: 15094389]
98. Tsan M-F, Gao B. Endogenous ligands of Toll-like receptors. *J Leukoc Biol.* 2004; 76:514–9. [PubMed: 15178705]
99. Tsan M-F, Gao B. Heat shock proteins and immune system. *J Leukoc Biol.* 2009; 85:905–10. [PubMed: 19276179]
100. Bausinger H, Lipsker D, Ziylan U, Manie S, Briand JP, Cazenave JP, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. *Eur J Immunol.* 2002; 32:3708–13. [PubMed: 12516564]
101. de Jong PR, Schadenberg AW, Jansen NJ, Prakken BJ. Hsp70 and cardiac surgery: Molecular chaperone and inflammatory regulator with compartmentalized effects. *Cell Stress Chaperones.* 2009; 14:117–31. [PubMed: 18668350]
102. Ortega E, Hinchado MD, Martin-Cordero L, Asea A. The effect of stress-inducible extracellular Hsp72 on human neutrophil chemotaxis: A role during acute intense exercise. *Stress.* 2009; 12:240–9. [PubMed: 18850491]
103. Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. *J Immunol.* 2009; 182:1449–559. [PubMed: 19155492]
104. Kovalchin JT, Wang R, Wagh MS, Azoulay J, Sanders M, Chandawarkar RY. In vivo delivery of heat shock protein 70 accelerates wound healing by up-regulating macrophage-mediated phagocytosis. *Wound Repair Regen.* Mar-Apr;2006 14(2):129–37. [PubMed: 16630101]
105. Wang R, Kovalchin JT, Muhlenkamp P, Chandawarkar RY. Exogenous heat shock protein 70 binds macrophage lipid raft microdomain and stimulates phagocytosis, processing, and MHC-II presentation of antigens. *Blood.* Feb 15; 2006 107(4):1636–42. [PubMed: 16263790]
106. Wang R, Town T, Gokarn V, Flavell RA, Chandawarkar RY. HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and PI3K pathways. *J Surg Res.* Nov; 2006 136(1):58–69. [PubMed: 16979664]

107. Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumor cells: A recognition structure for natural killer cells. *J Immunol.* 1997; 158:4341–50. [PubMed: 9126997]
108. Multhoff G, Pfister K, Gehrman M, Hantschel M, Gross C, Hafner M, et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. *Cell Stress Chaperones.* 2001; 6:337–44. [PubMed: 11795470]
109. Qiao Y, Liu B, Li Z. Activation of NK cells by extracellular heat shock protein 70 through induction of NKG2D ligands on dendritic cells. *Cancer Immun.* 2008; 8:12. [PubMed: 18613644]
110. Horn P, Kalz A, Lim CL, Pyne D, Saunders P, Mackinnon L, et al. Exercise-recruited NK cells display exercise-associated eHSP-70. *Exerc Immunol Rev.* 2007; 13:100–11. [PubMed: 18198664]
111. Javid B, MacAry PA, Lehner PJ. Structure and function: Heat shock proteins and adaptive immunity. *J Immunol.* 2007; 179:2035–40. [PubMed: 17675458]
112. Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy: Role of heat shock protein exposure on dying tumor cells. *Cell Cycle.* 2007; 6:1962–5. [PubMed: 17721082]
113. Wang XY, Kaneko Y, Repasky E, Subjeck JR. Heat shock proteins and cancer immunotherapy. *Immunol Invest.* 2000; 29:131–7. [PubMed: 10854181]
114. Tytell M, Greenberg SG, Lasek RJ. Heat shock-like protein is transferred from glia to axon. *Brain Res.* 1986; 363:161–4. [PubMed: 3947949]
115. Johnson AD, Berberian PA, Bond MG. Effect of heat shock proteins on survival of isolated aortic cells from normal and atherosclerotic cynomolgus macaques. *Atherosclerosis.* 1990; 84:111–9. [PubMed: 2282091]
116. Robinson MB, Tidwell JL, Gould T, Taylor AR, Newbern JM, Graves J, et al. Extracellular heat shock protein 70: A critical component for motoneuron survival. *J Neurosci.* 2005; 25:9735–45. [PubMed: 16237177]
117. Tidwell JL, Houenou LJ, Tytell M. Administration of Hsp70 in vivo inhibits motor and sensory neuron degeneration. *Cell Stress Chaperones.* 2004; 9:88–98. [PubMed: 15270081]
118. Sharma M, Ganguly NK, Chaturvedi G, Thingnam SKS, Majumdar S, Suri RK. A possible role of HSP70 in mediating cardioprotection in patients undergoing CABG. *Mol Cell Biochem.* 2003; 247:31–6. [PubMed: 12841628]
119. Dybdahl B, Wahba A, Haaverstad R, Kirkeby-Garstad I, Kierulf P, Espevik T, et al. On-pump versus off-pump coronary artery bypass grafting: more heat-shock protein 70 is released after on-pump surgery. *Eur J Cardiothorac Surg.* Jun; 2004 25(6):985–92. [PubMed: 15144999]
120. Kimura F, Itoh H, Ambiru S, Shimizu H, Togawa A, Yoshidome H, et al. Circulating heat-shock protein 70 is associated with postoperative infection and organ dysfunction after liver resection. *Am J Surg.* Jun; 2004 187(6):777–84. [PubMed: 15191875]
121. Pockley AG, De Faire U, Kiessling R, Lemne C, Thulin T, Frostegard J. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. *J Hypertens.* Sep; 2002 20(9):1815–20. [PubMed: 12195124]
122. Pockley AG, Georgiades A, Thulin T, de Faire U, Frostegard J. Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. *Hypertension.* Sep; 2003 42(3):235–8. [PubMed: 12900429]
123. Dybdahl B, Slordahl SA, Waage A, Kierulf P, Espevik T, Sundan A. Myocardial ishaemia and the inflammatory response: Release of heat shock protein 70 after myocardial infarction. *Heart.* 2005; 91:299–304. [PubMed: 15710705]
124. Genth-Zotz S, Bolger AP, Kalra PR, von Haehling S, Doehner W, Coats AJS, et al. Heat shock protein 70 in patients with chronic heart failure: Relation to disease severity and survival. *Int J Cardiol.* 2003; 96:397–401. [PubMed: 15301893]
125. Fukushima A, Kawahara H, Isurugi C, Syoji T, Oyama R, Sugiyama T, et al. Changes in serum levels of heat shock protein 70 in preterm delivery and pre-eclampsia. *J Obstet Gynaecol Res.* 2005; 31:72–7. [PubMed: 15669997]

126. Adewoye AH, Klings ES, Farber HW, Palaima E, Bausero MA, McMahon L, et al. Sick cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. *Am J Hematol.* 2005; 78:240–2. [PubMed: 15726596]
127. Oglesbee MJ, Herdman AV, Passmore GG, Hoffman WH. Diabetic ketoacidosis increases extracellular levels of the major inducible 70-kDa heat shock protein. *Clin Biochem.* 2005; 38:900–4. [PubMed: 16009359]
128. Wheeler DS, Fisher LE, Catravas JD, Jacobs BR, Carcillo JA, Wong HR. Extracellular hsp70 levels in children with septic shock. *Pediatr Crit Care Med.* May; 2005 6(3):308–11. [PubMed: 15857530]
129. Lai Y, Kochanek PM, Adelson PD, Janesko K, Ruppel RA, Clark RS. Induction of the stress response after inflicted and non-inflicted traumatic brain injury in infants and children. *J Neurotrauma.* Mar; 2004 21(3):229–37. [PubMed: 15115598]
130. Ganter MT, Ware LB, Howard M, Roux J, Gartland B, Matthay MA, et al. Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury. *Am J Physiol Lung Cell Mol Physiol.* Sep; 2006 291(3):L354–61. [PubMed: 16679378]
131. Mueller T, Bidmon B, Pichler P, Arbeiter K, Ruffingshofer D, VanWhy SK, et al. Urinary heat shock protein-72 excretion in clinical and experimental renal ischemia. *Pediatr Nephrol.* 2003; 18:97–9. [PubMed: 12579395]
132. Quintana FJ, Cohen IR. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. *J Immunol.* 2005; 175:2777–82. [PubMed: 16116161]
133. Su F, Nguyen ND, Wang Z, Cai Y, Rogiers P, Vincent JL. Fever control in septic shock: Beneficial or harmful? *Shock.* 2005; 23:516–20. [PubMed: 15897803]
134. Pittet JF, Lee H, Morabito D, Howard MB, Welch WJ, Mackersie RC. Serum levels of Hsp 72 measured early after trauma correlate with survival. *J Trauma.* Apr; 2002 52(4):611–7. [PubMed: 11956372]
135. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. *J Natl Cancer Inst.* Oct 6; 1993 85(19):1558–70. [PubMed: 8411230]
136. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. *Apoptosis.* Jan; 2003 8(1):61–70. [PubMed: 12510153]
137. Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, et al. TNF-alpha decreases hsp 27 in human blood mononuclear cells: involvement of protein kinase c. *Life Sci.* Dec 23; 2006 80(3):181–6. [PubMed: 17069861]
138. Sheth K, De A, Nolan B, Friel J, Duffy A, Ricciardi R, et al. Heat shock protein 27 inhibits apoptosis in human neutrophils. *J Surg Res.* Jul; 2001 99(1):129–33. [PubMed: 11421614]
139. De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. *J Immunol.* Oct 1; 2000 165(7):3951–8. [PubMed: 11034403]
140. Rayner K, Chen YX, McNulty M, Simard T, Zhao X, Wells DJ, et al. Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A. *Circ Res.* Jul 18; 2008 103(2):133–41. [PubMed: 18566345]
141. Laudanski K, De A, Miller-Graziano C. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. *Eur J Immunol.* Oct; 2007 37(10):2812–24. [PubMed: 17823891]
142. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, et al. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. *Invasion Metastasis.* 1997; 17(3):113–23. [PubMed: 9702938]
143. De AK, Roach SE. Detection of the soluble heat shock protein 27 (hsp27) in human serum by an ELISA. *J Immunoassay Immunochem.* 2004; 25(2):159–70. [PubMed: 15162919]
144. Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. *Am J Obstet Gynecol.* Jul; 2000 183(1): 18–21. [PubMed: 10920302]

145. Korneeva I, Caputo TA, Witkin SS. Cell-free 27 kDa heat shock protein (hsp27) and hsp27-cytochrome c complexes in the cervix of women with ovarian or endometrial cancer. *Int J Cancer*. Dec 10; 2002 102(5):483–6. [PubMed: 12432550]
146. Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS, et al. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. *Br J Cancer*. Jun; 1998 77(11):1875–9. [PubMed: 9667662]
147. Thor A, Benz C, Moore D 2nd, Goldman E, Edgerton S, Landry J, et al. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. *J Natl Cancer Inst*. Feb 6; 1991 83(3):170–8. [PubMed: 1988702]
148. Fanelli MA, Cuello Carrion FD, Dekker J, Schoemaker J, Ciocca DR. Serological detection of heat shock protein hsp27 in normal and breast cancer patients. *Cancer Epidemiol Biomarkers Prev*. Sep; 1998 7(9):791–5. [PubMed: 9752987]
149. Graner MW, Cumming RI, Bigner DD. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. *J Neurosci*. Oct 17; 2007 27(42):11214–27. [PubMed: 17942716]
150. Benn SC, Perrelet D, Kato AC, Scholz J, Decosterd I, Mannion RJ, et al. Hsp27 upregulation and phosphorylation is required for injured sensory and motor neuron survival. *Neuron*. Sep 26; 2002 36(1):45–56. [PubMed: 12367505]
151. Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. *Circulation*. Oct 12; 2004 110(15):2216–9. [PubMed: 15249501]
152. Miller H, Poon S, Hibbert B, Rayner K, Chen YX, O'Brien ER. Modulation of estrogen signaling by the novel interaction of heat shock protein 27, a biomarker for atherosclerosis, and estrogen receptor beta: mechanistic insight into the vascular effects of estrogens. *Arterioscler Thromb Vasc Biol*. Mar; 2005 25(3):e10–4. [PubMed: 15662019]
153. Park HK, Park EC, Bae SW, Park MY, Kim SW, Yoo HS, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. *Circulation*. Aug 29; 2006 114(9):886–93. [PubMed: 16923754]
154. Kardys I, Rifai N, Meilhac O, Michel JB, Martin-Ventura JL, Buring JE, et al. Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. *Clin Chem*. Jan; 2008 54(1):139–46. [PubMed: 18024525]
155. Martin-Ventura JL, Nicolas V, Houard X, Blanco-Colio LM, Leclercq A, Egido J, et al. Biological significance of decreased HSP27 in human atherosclerosis. *Arterioscler Thromb Vasc Biol*. Jun; 2006 26(6):1337–43. [PubMed: 16574891]
156. Efthymiou CA, Mocanu MM, de Bellerocche J, Wells DJ, Latchmann DS, Yellon DM. Heat shock protein 27 protects the heart against myocardial infarction. *Basic Res Cardiol*. Nov; 2004 99(6):392–4. [PubMed: 15309411]
157. Schimke I, Lutsch G, Schernes U, Kruse I, Dubel HP, Pregla R, et al. Increased level of HSP27 but not of HSP72 in human heart allografts in relation to acute rejection. *Transplantation*. Dec 27; 2000 70(12):1694–7. [PubMed: 11152098]
158. De Souza AI, Wait R, Mitchell AG, Banner NR, Dunn MJ, Rose ML. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. *Circ Res*. Jul 22; 2005 97(2):192–8. [PubMed: 15976317]
159. Ghayour-Mobarhan M, Sahebkar A, Parizadeh SM, Moohebati M, Tavallaie S, Rezakazemi-Bajestani SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. *Int J Exp Pathol*. 2008; 89:209–15. [PubMed: 18460073]
160. Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: Association with established cardiovascular risk factors. *Clin Chim Acta*. 2008; 395:42–6. [PubMed: 18501705]
161. Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. *Biochem Pharmacol*. 2009; 77:1763–72. [PubMed: 19428331]

162. Salminen A, Paimela T, Suuronen T, Kaarniranta K. Innate immunity meets with cellular stress at the IKK complex: Regulation of the IKK complex by HSP70 and HSP90. *Immunol Lett.* 2008; 117:9–15. [PubMed: 18282612]
163. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. *Vascul Pharmacol.* 2008; 49:134–40. [PubMed: 18692595]
164. Chung SW, Lee JH, Choi KH, Park YC, Eo SK, Rhim BY, et al. Extracellular heat shock protein 90 induces interleukin-8 in vascular smooth muscle cells. *Biochem Biophys Res Commun.* 2009; 378:444–9. [PubMed: 19028451]
165. Matthews R, Burnie J. The role of hsp90 in fungal infection. *Immunol Today.* Sep; 1992 13(9): 345–8. [PubMed: 1466751]
166. Matthews R, Hodgetts S, Burnie J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. *J Infect Dis.* Jun; 1995 171(6):1668–71. [PubMed: 7539475]
167. Matthews RC, Rigg G, Hodgett S, Carter T, Chapman C, Gregory C, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. *Antimicrob Agents Chemother.* 2003; 47:2208–16. [PubMed: 12821470]
168. Sutherland A, Ellis D. Treatment of a critically ill child with disseminated *Candida glabrata* with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole. *Pediatr Crit Care Med.* 2008; 9:e23–e5. [PubMed: 18843247]
169. Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. *Cell Stress Chaperones.* 2006; 11(2):116–28. Summer. [PubMed: 16817317]
170. Ryan MT, Naylor DJ, Hoj PB, Clark MS, Hoogenraad NJ. The role of molecular chaperones in mitochondrial protein import and folding. *Int Rev Cytol.* 1997; 174:127–93. [PubMed: 9161007]
171. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. *J Clin Invest.* Feb; 1999 103(4):571–7. [PubMed: 10021466]
172. Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. *Circulation.* Aug 23; 2005 112(8):1206–13. [PubMed: 16116071]
173. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. *Lancet.* Jan 30; 1993 341(8840): 255–9. [PubMed: 8093914]
174. Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, de Faire U. Association of serum antibodies to heat-shock protein 65 with borderline hypertension. *Hypertension.* Jan; 1997 29(1 Pt 1):40–4. [PubMed: 9039077]
175. Hoppichler F, Lechleitner M, Traweger C, Schett G, Dzien A, Sturm W, et al. Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. *Atherosclerosis.* Oct 25; 1996 126(2):333–8. [PubMed: 8902159]
176. Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J, et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. *Circulation.* Feb 27; 2001 103(8):1071–5. [PubMed: 11222468]
177. Schett G, Metzler B, Kleindienst R, Amberger A, Recheis H, Xu Q, et al. Myocardial injury leads to a release of heat shock protein (hsp) 60 and a suppression of the anti-hsp65 immune response. *Cardiovasc Res.* Jun; 1999 42(3):685–95. [PubMed: 10533609]
178. Zhang X, He M, Cheng L, Chen Y, Zhou L, Zeng H, et al. Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. *Circulation.* Dec 16; 2008 118(25):2687–93. [PubMed: 19106391]
179. Mandal K, Afzal AR, Brecker SJ, Poloniecki J, Xu Q, Jahangiri M. Association of serum soluble heat shock protein 60 with toll-like receptor 4 polymorphism and severity of coronary artery disease. *Heart.* May; 2006 92(5):683–5. [PubMed: 16614285]

180. Lewthwaite J, Owen N, Coates A, Henderson B, Steptoe A. Circulating human heat shock protein 60 in the plasma of British civil servants: relationship to physiological and psychosocial stress. *Circulation*. Jul 9; 2002 106(2):196–201. [PubMed: 12105158]
181. Xu Q, Schett G, Perschinka H, Mayr M, Egger G, Oberhollenzer F, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. *Circulation*. Jul 4; 2000 102(1):14–20. [PubMed: 10880409]
182. Xiao Q, Mandal K, Schett G, Mayr M, Wick G, Oberhollenzer F, et al. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a follow-up study. *Stroke*. Dec; 2005 36(12):2571–6. [PubMed: 16254226]
183. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J. Circulating heat shock protein 60 is associated with early cardiovascular disease. *Hypertension*. Aug; 2000 36(2):303–7. [PubMed: 10948094]
184. Wright BH, Corton JM, El-Nahas AM, Wood RF, Pockley AG. Elevated levels of circulating heat shock protein 70 (Hsp70) in peripheral and renal vascular disease. *Heart Vessels*. 2000; 15(1): 18–22. [PubMed: 11001481]
185. Jamin C, Dugue C, Alard JE, Jousse S, Saraux A, Guillevin L, et al. Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases. *Arthritis Rheum*. Dec; 2005 52(12):4028–38. [PubMed: 16320351]
186. Yokota SI, Hirata D, Minota S, Higashiyama T, Kurimoto M, Yanagi H, et al. Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune diseases: comparison with antibodies against other Hsp60 family proteins. *Cell Stress Chaperones*. Oct; 2000 5(4):337–46. [PubMed: 11048656]
187. Durai M, Gupta RS, Moudgil KD. The T cells specific for the carboxy-terminal determinants of self (rat) heat-shock protein 65 escape tolerance induction and are involved in the regulation of autoimmune arthritis. *J Immunol*. 2004; 172:2795–802. [PubMed: 14978079]
188. Moudgil KD, Durai M. Regulation of autoimmune arthritis by self-heat-shock proteins. *Trends Immunol*. 2008; 29:412–8. [PubMed: 18675587]
189. Prakken AB, van Eden W, Rijkers GT, Kuis W, Toebes EA, de Graeff-Meeder ER, et al. Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. *Arthritis Rheum*. Nov; 1996 39(11):1826–32. [PubMed: 8912504]
190. Prakken AB, van Hoeij MJ, Kuis W, Kavelaars A, Heynen CJ, Scholtens E, et al. T-cell reactivity to human HSP60 in oligo-articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint. *Immunol Lett*. Jun 1; 1997 57(1-3):139–42. [PubMed: 9232440]
191. de Kleer IM, Kamphuis SM, Rijkers GT, Scholtens L, Gordon G, De Jager W, et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. *Arthritis Rheum*. Jul; 2003 48(7):2001–10. [PubMed: 12847694]
192. Quintana FJ, Carmi P, Mor F, Cohen IR. Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. *J Immunol*. Sep 15; 2002 169(6):3422–8. [PubMed: 12218165]
193. Quintana FJ, Carmi P, Mor F, Cohen IR. DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide. *J Immunol*. Oct 1; 2003 171(7):3533–41. [PubMed: 14500649]
194. Quintana FJ, Carmi P, Cohen IR. DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. *J Immunol*. Nov 15; 2002 169(10):6030–5. [PubMed: 12421990]
195. Wheeler DS, Lahni P, Odoms K, Jacobs BR, Carcillo JA, Doughty LA, et al. Extracellular heat shock protein 60 (Hsp60) levels in children with septic shock. *Inflamm Res*. 2007; 56:216–9. [PubMed: 17588138]
196. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1

- receptor signaling pathway in innate immune cells. *J Biol Chem.* Aug 17; 2001 276(33):31332–9. [PubMed: 11402040]
197. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. *J Immunol.* Jan 15; 2000 164(2):558–61. [PubMed: 10623794]
198. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. *J Immunol.* Mar 15; 1999 162(6):3212–9. [PubMed: 10092772]
199. Flohe SB, Bruggemann J, Lendemans S, Nikulina M, Meierhoff G, Flohe S, et al. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. *J Immunol.* Mar 1; 2003 170(5):2340–8. [PubMed: 12594256]
200. Kilmartin B, Reen DJ. HSP60 induces self-tolerance to repeated HSP60 stimulation and cross-tolerance to other pro-inflammatory stimuli. *Eur J Immunol.* Jul; 2004 34(7):2041–51. [PubMed: 15214052]
201. Schuchmann M, Hermann F, Herkel J, van der Zee R, Galle PR, Lohse AW. HSP60 and CpGDNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells. *Immunol Lett.* May 15; 2004 93(2-3):199–204. [PubMed: 15158617]
202. Zanin-Zhorov A, Tal G, Shivtiel S, Cohen M, Lapidot T, Nussbaum G, et al. Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: effects on signaling, chemotaxis, and inflammation. *J Immunol.* Jul 1; 2005 175(1):276–85. [PubMed: 15972659]
203. Osterloh A, Meier-Stiegen F, Veit A, Fleischer B, von Bonin A, Breloer M. Lipopolysaccharide-free heat shock protein 60 activates T cells. *J Biol Chem.* Nov 12; 2004 279(46):47906–11. [PubMed: 15371451]
204. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. *J Immunol.* Sep 15; 2005 175(6):3594–602. [PubMed: 16148103]
205. Hartman DJ, Hoogenraad NJ, Condron R, Hoj PB. Identification of a mammalian 10-kDa heat shock protein, a mitochondrial chaperonin 10 homologue essential for assisted folding of trimeric ornithine transcarbamoylase in vitro. *Proc Natl Acad Sci U S A.* Apr 15; 1992 89(8):3394–8. [PubMed: 1348860]
206. Quinn KA, Athanasas-Platsis S, Wong TY, Rolfe BE, Cavanagh AC, Morton H. Monoclonal antibodies to early pregnancy factor perturb tumour cell growth. *Clin Exp Immunol.* Apr; 1990 80(1):100–8. [PubMed: 2323098]
207. Morton H, Cavanagh AC, Athanasas-Platsis S, Quinn KA, Rolfe BE. Early pregnancy factor has immunosuppressive and growth factor properties. *Reprod Fertil Dev.* 1992; 4(4):411–22. [PubMed: 1461992]
208. Athanasas-Platsis S, Somodevilla-Torres MJ, Morton H, Cavanagh AC. Investigation of the immunocompetent cells that bind early pregnancy factor and preliminary studies of the early pregnancy factor target molecule. *Immunol Cell Biol.* Aug; 2004 82(4):361–9. [PubMed: 15283845]
209. Zhang B, Walsh MD, Nguyen KB, Hillyard NC, Cavanagh AC, McCombe PA, et al. Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed-type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. *J Neurol Sci.* Aug 15; 2003 212(1-2):37–46. [PubMed: 12809997]
210. Morton H, McKay DA, Murphy RM, Somodevilla-Torres MJ, Swanson CE, Cassady AI, et al. Production of a recombinant form of early pregnancy factor that can prolong allogeneic skin graft survival time in rats. *Immunol Cell Biol.* Dec; 2000 78(6):603–7. [PubMed: 11114970]
211. Johnson BJ, Le TT, Dobbin CA, Banovic T, Howard CB, Flores Fde M, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. *J Biol Chem.* Feb 11; 2005 280(6):4037–47. [PubMed: 15546885]
212. Malhotra V, Wong HR. Interactions between the heat shock response and the nuclear factor-kappaB signaling pathway. *Crit Care Med.* 2002; 30:S89–S95.

213. Wong HR. Potential protective role of the heat shock response in sepsis. *New Horiz.* 1998; 6:194–200. [PubMed: 9654326]

Table 1

Major heat shock protein families

NAME	SIZE (KDA)	LOCALIZATION	BACTERIAL HOMOLOG	SOME KNOWN AND POSSIBLE FUNCTIONS
Ubiquitin	8	Cytosol/nucleus	—	Nonlysosomal degradation pathways
HSP 27 (HSPB1)	27	Cytosol/nucleus	—	Regulator of actin cytoskeleton; molecular chaperone; cytoprotection
Heme oxygenase	32	Bound to ER, extends to cytoplasm	—	Degradation of heme to bilirubin; resistance to oxidant stress
HSP 47	47	ER	—	Collagen chaperone
HSP 60 (HSPD)	60	Mitochondria	Gro EL	Molecular chaperone
HSP 70 (HSPA)	72	Cytosol/nucleus	Dna K	Highly stress inducible; involved in cytoprotection against diverse agents
	73	Cytosol/nucleus	—	Constitutively expressed chaperone
HSP 90 (HSPC)	90	Cytosol/nucleus	htpG	Regulation of steroid hormone activity
HSP 110	110	Nucleolus/cytosol	Clp family	Protects nucleoli from stress

Table 2

“Leaderless” proteins involved in the host immune response.

PROTEIN	EXTRACELLULAR FUNCTION	INTRACELLULAR FUNCTION
IL-1 α	Pro-inflammatory cytokine	Activator of transcription
IL-1 β	Pro-inflammatory cytokine	-
IL-18	Pro-inflammatory cytokine	-
Caspase I (ICE)	?	IL-1/IL-18 converting enzyme
HMGB1	Pro-inflammatory cytokine	Chromatin component
IL-16	Pro-inflammatory cytokine	-
MIF	Pro-inflammatory cytokine	Transcription factor modulator